| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02422368 Details | 2022-01-10 Interventional | 2/3 | 0 | Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Eye Diseases Graves Ophthalm… Thyroid Disease… Thyroid Eye Dis… | Do not access to the drug - | |||
| NCT04338828 Details | 2022-01-06 Interventional | 2 | 47 | Nitric Oxide COVID-19 Infections COVID19 | Absence of patients meeting criteria following initial COVID surge. DMSB recommended analysis
of results to date and early closure. - | |||
| NCT03386214 Details | 2022-01-06 Interventional | 1 | 8 | Pevonedistat Primary Myelofi… Myelofibroses | Sponsor stopped development of pevonedistat - | |||
| NCT00637832 2007-000222-51 Details | 2022-01-06 Interventional | 2 | 1 | Cyclophosphamid… Doxorubicin Liposomal doxor… Prednisolone Rituximab Vincristine Lymphoma Lymphoma, Folli… | no information - | |||
| NCT04353271 Details | 2022-01-03 Interventional | 2/3 | 3 | Hydroxychloroqu… COVID-19 Coronavirus Inf… Corona Virus In… Covid 19 | FDA recommendations to not use outside of the hospital setting or in a clinical trial due to
the risk of cardiac arrhythmias - | |||
| NCT01150890 2010-019544-39 Details | 2022-01-03 Interventional | 2 | 130 | Brodalumab Crohn Disease Crohn's Disease | The study was terminated early based on an imbalance in worsening Crohn's disease in active
treatment groups - | |||
| NCT02228382 2013-003250-25 Details | 2021-12-30 Interventional | 4 | 163 | Bosutinib Leukemia Leukemia, Myelo… Leukemia, Myelo… Philadelphia Ch… Previously Trea… | - - | |||
| NCT03370120 2017-003241-26 Details | 2021-12-29 Interventional | 2 | 406 | Padsevonil Drug Resistant … Epilepsy Seizures Drug-Resistant … Focal-Onset Sei… | Based on available data, UCB has decided to stop development of padsevonil as adjunctive
treatment of focal-onset seizure - | |||
| NCT01380028 2009-015524-28 Details | 2021-12-28 Interventional | 3 | 162 | Prednisone Hematoma Hematoma, Subdu… Hematoma, Subdu… Hematoma, Subdu… Chronic Intracr… | successfull Interim Analysis - | |||
| NCT01199302 2010-020881-53 Details | 2021-12-28 Interventional | 2 | 67 | Brodalumab Crohn Disease Crohn's Disease | The study was terminated early based on an imbalance in worsening Crohn's disease in active
treatment groups. - | |||
| NCT01123707 2010-018860-17 Details | 2021-12-22 Interventional | 3 | 173 | Aripiprazole Escitalopram Depression Depressive Diso… Depressive Diso… Major Depressiv… | The study was terminated early due to Sponsor decision; no safety issues. The study was terminated early due to Sponsor decision; no safety issues. | |||
| NCT00372073 Details | 2021-12-22 Interventional | 2 | 187 | Roscovitine Carcinoma, Non-… Lung Neoplasms Non-small Cell … | - - | |||
| NCT01111565 2010-018859-97 Details | 2021-12-21 Interventional | 3 | 137 | Aripiprazole Escitalopram Depression Depressive Diso… Depressive Diso… Major Depressiv… | The study was terminated early due to Sponsor decision, closure of this combination therapy
program is unrelated to any safety issues, no signals of concern. The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern. | |||
| NCT03050814 Details | 2021-12-20 Interventional | 2 | 30 | Avelumab Bevacizumab Capecitabine Fluorouracil Leucovorin Oxaliplatin Colorectal Neop… Colorectal Aden… Colorectal Canc… Colorectal Carc… Colorectal Tumo… | Terminated after an unplanned interim efficacy analysis. - | |||
| NCT04648826 Details | 2021-12-17 Interventional | 1/2 | 0 | Azacitidine Carcinoma, Rena… Lung Neoplasms Neoplasm Metast… Neoplasms Neoplasms, Germ… Sarcoma Epithelial Mali… Germ Cell Tumor… Melanomas Pulmonary Metas… Sarcomas | Due to notification from EMD Serono, for Bintrafusp alfa (M7824) regarding an observed increase
in the frequently of early progression and death. - | |||
| NCT03654729 Details | 2021-12-17 Interventional | 3 | 291 | Edetic Acid Pyridoxal Phosp… Colorectal Neop… Peripheral Nerv… Chemotherapy-in… Colorectal Canc… | On 23 January 2020, the Sponsor announced that the United States (US) Food and Drug
Administration (FDA) had issued a clinical hold in the US of the POLAR program. - | |||
| NCT00983437 Details | 2021-12-17 Interventional | 3 | 49 | Modafinil Brain Injuries Brain Injuries,… Sleepiness Wounds and Inju… Traumatic Brain… | Study has been stopped by sponsor decision The sponsor's decision to terminate the study early resulted in the small number of study participants, and related limitations to the interpretation of the study results. | |||
| NCT01510184 Details | 2021-12-16 Interventional | 3 | 79 | Antibodies, Mon… Rituximab Lymphoma Lymphoma, B-Cel… Lymphoma, Folli… Lymphoma, Large… Diffuse Large B… Follicle Center… | - The study was terminated early due to a sponsor business decision. | |||
| NCT04345861 Details | 2021-12-15 Interventional | 2/3 | 7 | Azithromycin Hydroxychloroqu… COVID-19 Coronavirus Inf… Pneumonia Pneumonia, Vira… Coronavirus Inf… | halted prematurely. - | |||
| NCT03564145 Details | 2021-12-15 Interventional | 3 | 547 | Benzoyl Peroxid… Rosacea Papulopustular … | Per protocol, the Sponsor could terminate the study once 300 participants completed a total of
28 weeks of treatment and 100 participants completed a total of 52 weeks. - |